NKGEN BIOTECH INC (NKGN)
US65488A1016 - Common Stock
NKGen Biotech Announces Upcoming Presentation on Autologous NK Cell Therapy at the 5th International Cell & Gene Therapy China Summit & Exhibition
SANTA ANA, Calif., May 16, 2024 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (Nasdaq: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company...
NKGen Biotech Presents Updated NK Cell Therapy Data for Neurodegenerative Disease at the 12th Annual Alzheimer’s & Parkinson’s Drug Development Summit
In vitro studies with SNK01 have shown a direct ability to phagocytose and digest amyloid and alpha-synuclein proteins while also secreting...
NKGen Biotech Announces Upcoming Publication at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
SANTA ANA, Calif., April 24, 2024 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (Nasdaq: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology...
What's Going On With Nano-Cap NKGen Biotech Stock On Monday?
NKGen Biotech Inc (NASDAQ:NKGN) shares traded higher on Monday, with a strong session volume of 19.25 million, compared to an average 100-day volume of 2.85 million, according to data from Benzinga Pro. However, there is no news to justify the +20% increase in the stock price. NKGen Biotech will present details about its NK cell therapy for neurodegenerative disease, review its preclinical data for Parkinson’s disease, and highlight clinical safety and efficacy data from the recently completed P
NKGen Biotech Announces Upcoming Presentation on SNK01 NK Cell Therapy in Neurodegenerative Disease at the 12th Annual Alzheimer’s & Parkinson’s Drug Development Summit
SANTA ANA, Calif., April 18, 2024 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (Nasdaq: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology...
NKGN Stock Earnings: NKGen Biotech Reported Results for Q4 2023
NKGen Biotech just reported results for the fourth quarter of 2023.
NKGen Biotech Secures Additional Financing of $5 Million to Continue Advancing Its Clinical Programs
The Company’s neurodegenerative clinical program remains on track, with continued advancement of the Alzheimer’s Phase 2 trial and anticipation of...
NKGen Biotech Presents Additional Phase 1 Clinical Trial Data in Alzheimer’s Disease at the Tau2024 Global Conference
SNK01 autologous NK cell therapy demonstrated a positive effect on cerebral spinal fluid (“CSF”) and plasma Tau proteins in Alzheimer’s patients. The...
Why Is Infobird (IFBD) Stock Up 63% Today?
Infobird stock is rising higher on Wednesday as shares of IFBD stock experience heavy trading this morning after a recent reverse split.
Why Is NKGen Biotech (NKGN) Stock Up 62% Today?
NKGen Biotech stock is experiencing heavy trading on Wednesday that has shares of NKGN rallying higher in pre-market trading.
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
We're starting Wednesday with a breakdown of the biggest pre-market stock movers traders will want to keep an eye on this morning!
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
It's time to start off trading this morning with a breakdown of the biggest pre-market stock movers worth watching on Tuesday!
Passage of the Amendment to the Advanced Regenerative Biotech Act a Positive Catalyst for Korean and Japanese Cell Therapy Companies
New York, Feb 7, 2024 - (Plato Data) - On Thursday February 2, 2024, the bio industry welcomed the parliament’s passage of a bill that adds regenerative medicine organizations to the list of those considered for human cell management business licenses. The National Assembly passed the “Amendment to the Act on Safety and Support for Advanced Regenerative Medicine and Advanced Biopharmaceuticals” in a plenary session paving the way for certain next generation NK Cell Therapy companies to recognized as a licensed management business.
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
We're starting off trading on Tuesday with a look into the biggest pre-market stock movers traders need to keep an eye on today!